The BCL-6 gene is known to be located on chromosome 3q27, at the breakpoint of the 3q27-associated translocations that occur frequently in human nomHodgkin's lymphomas (NHLs). To identify the BCL-6 protein, two antibodies that recognized distinct domains of this protein were raised in rabbits. Immunoprecipitation and immunoblotting of lysates of BCL-6-expressing cells using both antibodies showed a broad 92-to 98-kD band. Dephosphorylation of BCL-6 protein reduced the size of this band to 87 kD, suggesting that BCL-6 may be expressed in a phosphorylated HROMOSOMAL TRANSLOCATIONS involving 3q27 are found in some non-Hodgkin's lymphomas (NHLs), especially diffuse large B-cell lymphomas (DLBs)."~ BCL-6, also called LAZ3 or BCLS, is a recently found gene located on 3q27, at the exact breakpoint of this translocation. It encodes a putative zinc finger protein that may act as a transcriptional regulator."3 Rearrangements of the BCL-6 gene have been shown mostly on the same major translocation cluster on chromosome 3q27.'" A large series of NHLs have been analyzed for rearrangement of the BCL-6 gene, showing that this gene alteration is relatively frequent in B-cell NHLs, especially those of aggressive histology such as DLBs, although it is also found in a small proportion of low-grade B-NHLs such as follicular lymph om as.'^"' Although data on alterations of BCL-6 gene have been accumulating, little is known about its products. Preliminary studies have demonstrated BCL-6 mRNA to be expressed preferentially in some B-cell lines and B-NHLS,'.~ suggesting a possible biologic function of BCL-6 protein in B cells. However, identification of the BCL-6 protein has not been reported so far. Some other zinc finger proteins such as EGRl are known to play important roles in leukocyte differentiation." However. no findings have ever been presented on the physiologic functions of BCL-6 protein. Understanding of the structure and function of BCL-6 protein appears to be important for clarifying the 
pathologic role of BCL-6 protein in lymphomagenesis. In the present study, we have identified the BCL-6 protein as a 92-to 98-kD phosphoprotein that is expressed in both normal and neoplastic B cells at a specific level of differentiation, ie, germinal center B cells.
MATERIALS AND METHODS

Cells and tissue samples.
Saos-2 cells, derived from human osteosarcoma, were cultured in Dulbecco's Modified Eagle's medium (DMEM; Cosmo Bio, Tokyo, Japan) containing 10% vollvol fetal calf serum (FCS) at 37°C in a humidified air atmosphere with 5% vol/vol CO,. Raji and Bjab cella. derived from Burkitt's lymphoma, and Molt4 cells derived from T-cell leukemia were cultured in RPM1 l640 medium (GIBCO-BRL, Gaithersberg, MD) containing 10% vol/vol fetal bovine serum under the same conditions. The tissue specimens used in this study consisted of nonneoplastic human tonsils, 30 NHL biopsy specimens obtained directly from patients for diagnostic purposes, and human NHLs taken from nine patients and heterotransplanted and maintained in mice with severe combined immune deficiency (SCID mice). Human tonsillar tissues were obtained from patients undergoing tonsillectomy for reactive tonsillar hyperplasia. The tonsils, NHL biopsy specimens, and NHLs maintained in SCID mice were snap-frozen immediately after resection in n-hexane precooled with dry ice-acetone and stored at -80°C until used. Lymphomas maintained in SCID mice are particularly useful for the quantitative detection of BCL-6 mRNA and protein, as these tumor tissues are free from contamination by nonneoplastic human lymphocytes, whereas biopsy specimens are likely to contain nonneoplastic BCL-6-expressing cells. The details of engraftment and maintenance of NHLs in SClD mice were reported previously." The histopathologic classification of NHLs was carried out by following the Revised European-American Classification of Lymphoid Neoplasms (REAL)" and the details of the NHLs examined in this study are listed in Tables I and 2 .
Isolution .fa Probe by Reverse Transcriptase-Pol~~mevclse Chain Reuction (RT-PCR)
The total RNA was extracted from a B-cell line, Raji, which is known to express the BCL-6 transcript,' using the RNAzol B method (Biotecx Laboratories, Houston, TX), which is based on a modified acid guanidine thiocyanate-phenol-chloroform rnethod.I4 Five micrograms of the total RNA extracted from Raji cells was used for synthesis of the first strand cDNA using a First-Strand cDNA Synthesis kit (Pharmacia Biotech, Uppsala, Sweden) and this cDNA was used as a template for the following PCR. GAGAACGGGGCC-3', and that of the reverse primer (IR) was 5'-TTTCCCGGGGAAGGGGCTGGAGACGAAAG-3'. An Air Thermo-Cycler 1605 (Idaho Technology, Idaho Falls, ID), the Optim buffer system (Idaho Technology), and Taq DNA polymerase (Boehringer Mannheim Biochemicals, Mannheim, Germany) were used for PCR, the amplification protocol of which consisted of 30 cycles of denaturation at 94°C for 5 seconds, annealing at 55°C for 2 seconds, and extension at 72°C for 7 seconds. The PCR product (IFR) was digested at the BarnHI and Sma I sites included in the PCR primers, cloned into PUCl19, and sequenced. This cloned DNA was digested with BamHI and Sma I and the DNA insert thus obtained was gel-purified and used as a probe to screen a cDNA library to determine the full-length cDNA of BCL-6.
Screening of a cDNA Library
A AgtlO cDNA library prepared from a human skeletal muscle that had been shown to express the BCL-6 transcript was purchased from Clontech Laboratories (Palo Alto, CA).2.3 A total of 5 X 105 plaques were screened with the 1FR-probe labeled with ["PIdCTP and hybridized at 65°C. Twenty positive phage clones were identified, and the one with the largest DNA insert was digested with EcoRI and fractionated by electrophoresis in 1% wt/vol agarose gel. As the sequence of BCL-6 cDNA contains one EcoRI site, the two inserted DNA fragments with expected sizes of about 0.4 and 2.1 kb were cut out by this digestion. They were eluted and each one was cloned into the pBluescript I1 KS+ vector (Stratagene, La Jolla, CA). The sequences of the two clones were checked and found to be identical to those of BCL-6 cDNA reported previously, nucleotides 4 to 2110, and 2111 to 2538 (GenBank, Bethesda, MD, U00115), respectively.' These EcoRI-digested DNA fragment inserts were ligated to each other and cloned into the EcoRI site of the pBluescript I1 KS+ vector to obtain full-length BCL-6 cDNA.
Synthesis and Pur$cation of Recombinant BCL-6 Protein
Plasmids encoding the NH,-terminal region (amino acids 2 to 181) and middle portion (amino acids 230 to 426) of BCL6 protein2.' were generated by amplifying the BCL-6 cDNA by PCR using the forward primer 2F, 5'-lTTGGATCCGCCTCGCCGTGAC-AGCTGT-3', and reverse primer 2R, 5'-mCCCGGGTCAGGC-AAAGGCTCTGCTCTCACA-3', for the NH2-terminal region of BCL-6 and the forward primer 3F, 5'-TTGGATCCCTCCCATGT-GATAGTGCCAGGCCA-3', and reverse primer 3R, 5'TTTCCC-GGGTCACTGGAGGTCAAGGTCTCAGGCTC-3', for the middle portion. The PCR products, designated 2FR and 3FR, respectively, were digested at the BarnHI and Srna 1 sites included in the primers and ligated in frame into the BarnHI and SmaI sites present in the pGEX-2T vector (Pharmacia Biotech). The resulting BCL-6-2FR and BCL-6-3FR proteins were fused to glutathione Stransferase (GST) to produce GST-BCL-6-2FR and GST-BCL-6-3FR, respectively, expressed in Escherichia coli and affinity-purified using glutathione-Sepharose, as described previously.'5 The purities and concentrations of the eluted proteins were assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Antibodies
The purified GST-BCL-6-2FR and GST-BCL-6-3FR proteins were used to immunize rabbits to raise anti-BCL-6 polyclonal antibodies. The immune sera were taken from rabbits, partially purified twice by ammonium sulfate precipitation" and the precipitates were solubilized with l x phosphate-buffered saline (PBS). Then, they were precleared by passage through GST-Sepharose columns to absorb the anti-GST antibodies and affinity-purified with antigen columns on which GST-BCL-6-2FR protein or GST-BCL-6-3FR protein was coupled to activated-CH Sepharose (Pharmacia Biotech). The purified antibodies, designated 2FR-1 Ab and 3FR-1 Ab directed against BCL-6-2FR and BCL-6-3FR proteins, respectively, were used in the following experiments.
Immunoprecipitation and Immunoblotting
Cells were lysed in SDS-modified RIPA buffer (0.1% wt/vol SDS, 40 mmol/L 2-[4-(2-hydroxyethyl)-l-piperazinyl]ethanesulfonic acid (HEPES)-NaOH (pH 7.4), 1% vol/vol Nonidet p-40 (NP40) (Nacalai Tesque, Kyoto, Japan), 0.5% wt/vol sodium deoxycholate, 150 mmol/L NaCl, 1 mmollL phenylmethylsulfonyl fluoride (PMSF), 10 mmol/L sodium pyrophosphate, 10 mmol/L sodium fluoride, 4 mmoVL EDTA, and 2 mmol/L sodium vanadate) on ice for 10 minutes and centrifuged at 15,000 rpm at 4°C for 20 minutes. The protein concentrations were measured using a BIO-RAD Protein Assay kit (BIO-RAD, Richmond, CA), according to the manufacturer's instructions. The protein lysates ( 2 mg) were incubated with the anti-BCL-6 antibodies at 4°C for 60 minutes, the immune-complexes were adsorbed to protein G-Sepharose (Pharmacia Biotech) and washed thoroughly with modified RIPA buffer (40 mmol/L HEPES-NaOH [pH 7.41, l % wt/vol NP40, 0.5% wt/vol sodium deoxycholate, 150 mmol/L NaCI, I mmol/L PMSF, I O mmol/L sodium pyrophosphate. I O mmol/L sodium fluoride. 4 mmol/L EDTA, and 2mmoVL sodium vanadate). The immunoprecipitates were boiled with Laemmli's sample buffer and then separated electrophoretically on SDS (7.59 wt/vol)-polyacrylamide gel. The Samples were transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA), which was blocked overnight in 10% wt/vol skim milk in 1 X TBS (Tris-buffered saline) at 4°C and then incubated with l0 pg/mL affinity-purified 2FR-l or 3FR-l Ab for I hour at 4°C. The filter was washed thoroughly with I X TBS containing 0.1% vol/vol Tween 20 and incubated with an alkaline phosphatase-conjugated antirabbit IgG antibody (Promega, Madison, WI) at 4°C for 30 minutes. After washing with I X TBS containing 0.1% wt/vol Tween 20, the filter was stained with 5-bromo-4-chloro-3-indolylphosphate p-toluidine salt (BCIP) and nitroblue tetrazolium chloride (NBT), according to the manufacturer's instructions (GIBCO-BRL, Gaithersburg, MD).
Trunsient Expression c$ BCL-6 by Electroporation
The full-length BCL-6 cDNA was cloned into the expression vector pMKIT-neo( +) containing the SRa promoter. Expression vectors were introduced by electroporation into Molt4 cells that do not express BCL-6' using Gene Pulser apparatus (BIO-RAD). Briefly, the cells were washed with 1 X PBS, resuspended at a density of l X IO' viable cells/mL in RPM11640 without FCS, and 0.4 mL cell suspension was used per electroporation in 0.4-cm cuvettes. A 10-pg aliquot of pMKIT-neo(+)-BCL-6 plasmid or pMKIT-neo(+) vector alone was added to the cuvette containing the Molt4 cells and electroporation was performed at 210 V and 960 pFD. Ten minutes after electroporation, the cells were placed into RPM11640 containing IO% vollvol FCS, incubated at 37°C for 40 hours, after which they were harvested and washed with 1 X PBS. The cell pellets were lysed with SDS-modified RIPA buffer, and the extracted proteins were subjected to immunoprecipitation and imrnunoblotting.
Indirect Immunojuorescence Cytochemistry
Saos-2 cells bearing the pMKIT-neo(+)-BCL-6 plasmid introduced by electroporation were plated on coverslips coated with collagen type TV (Nitta gelatin, Osaka, Japan) and incubated for at least 24 hours at 37°C. The cells were fixed for 5 minutes in methanol at -20°C rinsed three times with I X PBS containing 0.5% vol/vol Tween 20 (PBS/Tw) for 5 minutes each, then blocked with 10% vol/vol normal swine serum in 1 X PBS for 15 minutes, incubated with 2FR-1 Ab (10 yg/mL) for 1 hour at room temperature (RT), and washed three times with IX PBS/Tw. Next, the cells were incubated with fluorescein isothiocyanate (F1TC)-conjugated antirabbit IgG antibody (TAGO, Burlingame, CA) for 30 minutes at RT. the cells remaining on the coverslips were washed three times with 1 X PBS/Tw, stained with 1 pg/mL DAPI for 3 minutes, washed twice with 1 X PBS/Tw and then three more times with 1 X PBS, and the coverslips were mounted with 90% voVvol glycerol in 1 X PBS. The cells were observed under a Nikon fluorescence microscope (Nikon, Tokyo, Japan) and photographed.
Treatment of BCL-6 Protein With Potato-AcidPhosphatase (PA P )
The total lysates extracted from Bjab cells were immunoprecipitated with 2FR-l Ab. The immune complexes adsorbed to protein G-Sepharose were washed with simple RIPA buffer (40 mmol/L HEPES-NaOH pH 7.4, 1% vol/vol NP40, 1 mmoVL PMSF, and 0.15 mol/L NaCl) and incubated at 30°C for 60 minutes in 40 mmoll
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L piperazine-N,N'-bis(2-ethanesulfonic) acid (PIPES; pH 6.0) containing I mmol/L dithiothreitol in the presence or absence of 40 pgl mL PAP (Boehringer Mannheim)." Then, the samples were washed thoroughly with simple RIPA buffer, boiled with Laemmli's sample buffer, and subjected to immunoblotting.
Treatment of Cells With Tunicamycin
Bjab cells were incubated at 37°C with 2 pg/mL tunicamycin (Boehringer-Mannheim) for I O hours, harvested, the cell pellets were lysed with SDS-modified RIPA buffer, and the extracted proteins were subjected to immunoprecipitation and immunoblotting.
Immunohistochemistry
Nonneoplastic tonsils, NHL biopsy specimens, and NHLs maintained in SCID mice were subjected to immunohistochemistry with 2FR-I and 3FR-I Abs as the first reagents using the labeled avidinbiotin-peroxidase (LAB) method. A biotinylated swine-antirabbit antibody and peroxidase-labeled avidin (both from DAKOPATTS, Copenhagen, Denmark) were used as the second-and third-phase reagents, respectively, and the staining procedures of Hsu et allX were followed. Briefly, cryostat sections were fixed with 4% voll v01 paraformaldehyde in O.IN phosphate buffer (pH 7.4) and incubated with the first-, second-, and third-phase reagents successively at RT for 30 minutes each in a warm moist chamber at 37°C and washed with 1 X PBS (pH 7.4) between the steps. Diaminobenzidine tetrahydrochloride (Sigma, St Louis, MO) was used as the chromogen. The immunohistological results were evaluated as +, a large proportion (>50%) of the cells stained; +*, some cells (<50%) stained; -, unstained.
Double immunostaining using the LAB-peroxidase and alkaline phosphatase-anti-alkaline phosphatase (APAAP) methods in combination was used to ascertain the immunophenotype of the BCL-6-expressing cells. The immune reaction with 2FR-I Ab resulted in red coloration with ethylcarbazole solution (Histofine Kit; Nichirei, Tokyo, Japan), the chromogen for peroxidase and other leukocyte markers, and a blue color was generated with NBT solution (Nucleic acid detection kit; Boehringer-Mannheim), the chromogen for alkaline phosphatase. The following reagents (all from DAKOPATTS) were used in this study: L26 (anti-CD20), Leu4 (anti-CD3). KPI (anti-macrophage), DAKO-DRCI (anti-follicular dendritic cells), biotinylated swine-antirabbit IgG, goat-antimouse Ig antibody, peroxidase-labeled avidin, and mouse APAAP. The tissue sections were incubated with the first reagents (a mixture of diluted 2FR-1 Ab [rabbit] and one of the murine antibodies), then with the second reagents (a mixture of appropriately diluted biotin-labeled swineantirabbit IgG and goat-antimouse IgG) and finally with the thirdphase reagents (a mixture of LAB-peroxidase and APAAP). ,The color reaction for alkaline phosphatase with NBT was performed first followed by the aminoethyl-carbazol reaction for peroxidase.
Southern Blot Analysis
Genomic DNA was prepared from NHLs maintained in SCID mice and biopsy specimens by digestions with proteinase K in the presence of EDTA and SDS, followed by extraction with phenol." For Southern blotting, IO pg genomic DNA was digested with BarnHl or Xha I (TAKARA, Kyoto, Japan), electrophoresed in I% wt/vol agarose gel and transferred to a nylon membrane (Pall Biodyne Transfer Membrane; PALL Biosupport, East Hills, NY). A probe ST-l, corresponding to the intron I of the BCL6 gene: was a gift from Dr T. Miki (Tokyo Medical and Dental University, Tokyo, Japan) and the membrane was hybridized with this probe, which was labeled with ["PIdCTP using a Ready To Go DNA labeling kit (Pharmacia Biotech), according to the manufacturer's 
Northern Blot Analysis
The total RNA was extracted from NHLs maintained in SCID mice and biopsy tissues, as described above, 20 pg total RNA was electrophoresed through 1% wtlvol agarose gel containing 3% voll v01 formaldehyde and transferred to a nylon membrane. The membrane was hybridized at 42°C with the IFR-probe labeled with ["PIdCTP, washed with 0.2X SSC containing 0.1% wt/vol SDS at 65°C three times for 30 minutes each, and autoradiographed for 12 hours at -70°C with intensifying screens. The membrane was deprobed and rehybridized with a 0-actin probe as a control.
RESULTS
Detection of a BCL-6 Protein by Anti-BCL-6 Antibodies
(ZFR-I and 3FR-I Abs)
First, the specificity of the 2FR-1 Ab was examined. Immunoprecipitation and immunoblotting of lysates obtained from Bjab cells that expressed BCL-6 transcripts and Molt4 cells that did not3 showed that the 2FR-1 Ab detected a broad band with a molecular mass of 92-to 98-kD in Bjab, but not Molt4, cell lysates (Fig 1) . To confirm the specificity of 2FR-1 Ab, lysates of Molt4 cells into which the pMKITneo(+)-BCL-6 construct or pMKIT-neo(+) vector alone had been introduced were analyzed by immunoprecipitation and 
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also obtained when the lysates from Molt4 cells into which pMKIT-neo(+)-BCL-6 had been introduced were immunoprecipitated and immunoblotted with 3FR-1 Ab (data not shown). Further confirmation of the specificity of these antibodies for BCL-6 protein was provided by immunoprecipitation and immunoblotting using both these antibodies, which recognize a distinct domain of the protein. As shown in Fig  3, immunoprecipitates obtained from Bjab cells using 2FR-1 or 3FR-1 Ab exhibited identical 92-to 98-kD bands after immunoblotting with both antibodies, suggesting that both antibodies recognized BCL-6 protein specifically (Fig 3) .
Because the molecular mass of BCL-6 protein in SDS gels (92 to 98 kD) was larger than predicted size (79 kD),2.3 PAP treatment was performed to determine whether this discrepancy could be explained by phosphorylation of BCL-6 protein. As shown in Fig 4, when the immunoprecipitates obtained from Bjab cells using 2FR-1 Ab were incubated with PAP, the broad 92-to 98-kD band was flattened and its molecular mass decreased to approximately 87 kD (Fig  4) , suggesting that the different electrophoretic mobilities of the 87-and 92-to 98-kD bands were caused by phosphorylation differences. Treatment of Bjab cells with tunicamycin, in the same 92-to 98-kD band as untreated cells (data not shown), suggesting that N-linked glycosylation was not responsible for the different mobilities in SDS gels. cipitation and immunoblotting, was introduced either with the pMKIT-neo( +) vector alone or pMKIT-neo( +)-BCL-6 by electroporation and these cells were subjected to indirect immunoblotting. An identical 92-to 98-kD band was obimmunostaining. Positive staining was only observed in cells served in the former, but not on the latter, supporting the with introduced pMKIT-neo(+)-BCL-6 (Fig 5) and the imabove finding that 2FR-1 Ab recognized the BCL-6 protein munostaining reaction was observed only in the nuclei, not specifically (Fig 2) . An identical 92-to 98-kD band was in the cytoplasm. 
BCL-6 Protein Is Localized in the Nucleus
2FR-1 3FR-1
-I I
BCL-4 Protein I s Expressed Preferentially in Germinal Center B Cells
Human tonsils with reactive follicular hyperplasia were immunostained with 2FR-I or 3FR-1 Ab. Marked staining was observed predominantly in the nuclei of cells located in the germinal centers (Fig 6) . More than 70% of the cellular components of each germinal center were stained, and the staining intensities of the two major germinal center zones, the light and dark zones, did not differ, and neither did the immune reactions of the two antibodies. Stained cells were distributed evenly in the germinal centers. Larger nuclei tended to stain more intensely, but this was not a consistent finding. Lymphocytes in the mantle and T zones were not stained. A small number of stained cells was found in the marginal zone, but neither plasma cells nor fibroblasts were stained.
After double immunostaining, the germinal center and marginal zone cells, the nuclei of which were stained red by 2FR-1 Ab, also showed blue cell membrane staining with CD20 (anti-pan B cell), but not with CD3 (anti-panT cell), KP-I (antimacrophage), or DAKO-DRCI (anti-follicular dendritic cell), suggesting that the strongly immunostained cells in these zones were B cells. Meanwhile, a large number of CD20' cells in the marginal zone were not stained by 2FR-1 Ab, indicating that the BCL6' B cells constituted very small proportion of the marginal zone B cells (Fig 7) .
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Expression qf BCL6 Protein and mRNA in NHLs NHL biopsy specimens. Expression of BCL6 protein and mRNA in NHLs was studied and correlated with BCL-6 gene rearrangements. First, 30 NHLs obtained surgically were studied. Their histologic subtypes are listed in Table  1 . All the subtypes, other than DLBs and T-cell NHLs, were categorized as low-grade malignancies.*" Clear immunostaining of a large proportion of neoplastic cells with 2FR-1 Ab, categorized as +, was observed in 17 samples, partial positive reactions (+*) in 2, and no staining (-) in 1 1. The expression levels of BCL-6 in NHLs of a low-malignancy grade group were found to correlate exactly with their normal counterparts: immunostaining was not observed in 1/1 Bcell small lymphocytic lymphoma (the normal counterpart of which is the peripheral small B-cells), 1/1 lymphoplasmacytoid type (plasma cells and precursors), 2/2 mantle cell lymphomas (mantle zone B-cell), 2/2 marginal zone lymphomas (marginal zone B-cell), and 2/2 plasmacytomas, whereas intense immunostaining was observed in all 8 follicular lymphomas (germinal center B cells) (Fig 8) . In DLBs, classified as high-malignancy grade NHLs, a large proportion (10/1 I ) immunostained strongly with 2FR-1 Ab, whereas the remaining one (case TKT in Table 1 ) was unstained. All the T-NHLs were unstained, corresponding to their normal counterparts. The Northern blot analysis and immunohistologic results correlated well.
The rearrangement of BCL-6 genomic DNA was studied in 22 samples, 7 of which were found to be rearranged, whereas the remaining 15 were in the germ line. Two of the 7 rearranged NHLs were follicular lymphomas with high expression levels of BCL-6 protein and mRNA and the remaining 5 were DLBs, with high expression levels of BCL-6 protein.
NHLs maintained in SCID mice. Next, 9 NHLs (7 DLBs and 2 Burkitt's lymphomas) maintained in SCID mice were studied. All these NHLs showed B-cell phenotypes, determined by the presence of Ig or CD20, and were negative for IgD and CD5, suggesting that they were not at the differentiation level of peripheral small B or mantle cells. Clear nuclear staining with 2FR-1 Ab was observed in 7/9 of these NHLs. Clear immune reactions in the nuclei of positive cells were observed and the staining patterns appeared to be identical to those of the nonneoplastic germinal center B cells (Fig 8) . Furthermore, the immunohistologic results correlated well with those of the Northern blot analysis: weak Northern blotting bands were observed with 2/9 NHLs, both of which were not stained immunohistologically, whereas distinct expression was observed in 7/9, all of which stained immunohistochemically (Fig 9) .
BCL-6 gene rearrangement was observed in 3/9 NHLs in SCID mice. The expression levels of BCL-6 protein and mRNA differed in these gene-rearranged NHLs: in 2/3 (FMS17 and OMS19), high levels of BCL-6 protein and mRNA were expressed, whereas in the other (HMS1 l), the expression levels were very low (Table 2 ; Figs 9 and 10 ).
DISCUSSION
The present study was undertaken to clarify the nature of BCL-6 protein in human lymphoid tissues and lymphoid malignancies. For this purpose, two antibodies (2FR-1 and 3FR-1 Abs) were raised in rabbits using different recombinant BCL-6 proteins. Detailed studies of the purified antibodies showed that they were specific for the BCL-6 protein in immunoprecipitation, immunoblotting, and immunocytochemistry experiments. Using these antibodies, the BCL-6 protein was shown as a broad band with a molecular mass ranging from 92 to 98 kD, which was higher than predicted (79 kD).'.3 This discrepancy in the mobilities in SDS gels may be partly explained by the high content of prolihe in BCL-6 protein; up to 9.3% of its amino acid sequences contain proline. Such slow migration in SDS gels is well exemplified by some transcription factors such as c-Fos," Fra-l,'2 and FosB,'~ which are also rich in proline. Phosphorylation of the BCL-6 protein also appeared to be responsible for its slow migration. The BCL-6 protein was considered likely to be phosphorylated, because it was found to contain 14 putative proline-dependent phosphorylation consensus motifs3 In the present study, dephosphorylation of BCL-6 protein with PAP resulted in flattening of the broad 92-to 98-kD band and reduction of its molecular mass to 87 kD, suggesting that BCL-6 protein may be expressed in B cells in a phosphorylated form. As several transcription factor functions, such as regulation of nuclear tran~location,'~ DNA binding," and transactivation," are regulated directly by phosphorylation, our present results suggest strongly that the function of BCL-6 protein may be also regulated by phosphorylation.
In tissue sections, as well as in cells into which BCL-6 cDNA had been introduced by electroporation, the BCL-6 protein was found to be localized in the nuclei. This localiza- Table 2 ); (B) DLB (case TMS9 in Table 2 ), (C) follicular lymphoma I (case ITM in tion can be explained by the contemporary knowledge that BCL-6 is a member of the zinc-finger proteins, which are usually located in the nuclei and regulate transcription of various genes. Our study also showed that the BCL-6 protein is expressed preferentially in germinal center B cells, suggesting that it may play some role(s) in their differentiation processes, such as clonal expansion, hypermutation of Ig genes, clonal selection, andor differentiation into memory B cells or plasma cells.'7 Support for this hypothesis is provided by recent findings that some zinc finger proteins contribute to the differentiation of hematopoietic cells, as exemplified by EGRl, which is involved in differentiation of HL60 cells, a myeloblastic leukemia cell line, along the macrophage lineage." The results of further studies are awaited to establish the function of this protein in germinal center B cells.
Immunohistologic study is essential to assess the expression of BCL-6 protein in surgically excised NHL biopsy specimens, because they usually contain normal (nonneoplastic) lymphocytes that may or may not carry this protein and cell type-specific expression in these tissues cannot be evaluated by immunochemical methods, such as immunoblotting. Among the NHL subtypes, follicular lymphoma and Burkitt's lymphoma are regarded as the neoplastic counterparts of germinal center B cells." In the present study, in 39 NHLs consisting of these maintained in SCID mice and obtained at biopsy, 1/2 of the Burkitt's lymphomas and all 8 follicular lymphomas were shown to express high level of BCL-6 protein, suggesting that the consistent expression of BCL-6 protein in these NHLs reflected their normal counterparts, the germinal center B cells. Of 18 DLBs, 16 expressed high levels of BCL-6 protein, whereas no such expression could be detected in the remaining 2. High expression levels in samples without BCL-6 gene rearrangement may reflect their normal counterparts. Meanwhile, the 2 DLBs in which expression was undetectable showed no BCL-6 gene rearrangement. We postulate two explanations for the low expression of BCL-6 protein in such unrearranged DLBs: ( 1 ) the Southern blot analysis using the ST-l probe may not have covered the disrupted site in the putative transcriptional regulatory region that caused deregulation of transcription, thus leading to failure to detect rearrangement; and (2) the absence or low expression level of BCL-6 protein in some NHLs simply reflects the characteristics of their normal counterparts, which do not express this protein.
Chromosomal translocations at 8q24 in Burkitt's lymphomas and 14q32 in follicular lymphomas have been reported to cause transcriptional activation of genes locating at the breakpoint, such as c-rnyc".3" and hcl-2 respectively. In the present study, a high proportion of BCL-6-rearranged NHLs were found to express BCL-6 protein strongly, at the same levels as unrearranged NHLs. However, very low expression was noted in one of 10 gene-rearranged NHLs (HMS1 in Table 2 ). In this case, two speculative situations may be applicable: ( 1 ) BCL-6 gene rearrangement might have caused destruction of the putative transcriptional regulatory region and noncoding exon 1, resulting in deregulation of BCL-6 gene transcription; and (2) as the BCL-6 gene has been reported to have various translocation partners, such as 14q32, 22ql1, llq13, 12ql1, 12q24, Oq13, lq2 I , 2q23, 8q24, and 5q3 1 ,'.l" the transcriptional regulation of the BCL-6 gene may be restricted by these partner genes. To establish which, if either, hypothesis is correct, detailed molecular studies of rearranged BCL-6 genes, together with detailed analysis of partner genes, will be needed for each specific case.
Recently, Ofitt et al' reported that patients with DLBs with BCL-6 gene rearrangements have a more favorable clinical outcome than those with other DLBs. Because the present study showed a minor but definite gap between generearrangement and protein-expression, more precise data on patients' natural clinical courses may be obtained if such cases are studied at the protein level. Therefore, another large scale survey involving the use of immunohistochemistry is awaited. Furthermore, to determine the role of BCL-6 protein in lymphomagenesis, further intensive studies of its biologic functions, including its role in transcription, the significance of its phosphorylation, and its biologic roles in B-cell differentiation are required.
